Transcatheter procedure performed at The Christ Hospital using the Capstan Compass Robotic System SANTA CRUZ, Calif., Nov. 16, 2026 /PRNewswire/ — CAPSTAN MEDICAL® today announced the successful completion of its first U.S. robot-assisted transcatheter mitral valve replacement (TMVR)…
Coronary/Structural Heart
Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results
Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycardia and 44% mean reduction in premature ventricular contractions at latest assessment LX2020 generally well tolerated across 10 participants with no clinically significant complement activation U.S. Food and Drug Administration open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint to support potential accelerated approval of LX2020 Cash, cash equivalents and investments of $219.1 million expected to provide operational runway into 2028 Company to host webcast today at 8:00 AM ET NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced positive interim data from the ongoing HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). Across ten participants, including nine with at least 12 months of follow-up, treatment with LX2020 was generally well tolerated and associated with clinically meaningful reductions in arrhythmia burden, including non-sustained ventricular tachycardia (NSVT) and premature ventricular contractions (PVC), as well as improvement in measures of right ventricular function and patient-reported symptoms. Lexeo is now designing a pivotal study with NSVT as a primary surrogate endpoint to support potential accelerated approval. The final study design including the statistical analysis plan and confirmatory strategy remains subject to future discussions with the FDA. “These data further strengthen our confidence in LX2020 and its potential to address the underlying biology of PKP2-ACM,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “The magnitude and consistency of NSVT reduction far exceed what available therapies have historically achieved, underscoring how LX2020 could meaningfully improve outcomes for individuals with PKP2-ACM. Our regulatory discussions also provide important clarity on the path forward, including the FDA’s openness to the use of NSVT as a primary endpoint in a planned pivotal study given the well-established association between NSVT and sustained, life-threatening arrhythmic risk.” “For families living with PKP2 arrhythmogenic cardiomyopathy, the risks and uncertainties reach far beyond the clinic and into every part of daily life,” said Walker Frahm, Chief Executive Officer of the Foundation for Inherited Arrhythmias (FIA). “Our community has waited a long time for treatments that might address the underlying cause of this disease. Early results like these give ACM families reason to hope for better, more targeted care. We look forward to larger studies that build on these findings.” LX2020 Interim UpdateTen participants have been dosed in the HEROIC-PKP2 Phase I/II clinical trial, including three participants in Cohort 1 at the low dose (2×1013 vg/kg) and seven participants in Cohorts 2 and 3 at the high dose (6×1013 vg/kg). As of the October 15, 2026 data cutoff date, nine of ten participants reached at least 12 months of follow-up, with the remaining participant reaching nine months of follow-up. Safety and efficacy data are summarized for all ten participants at latest assessment. Clinical Data 80% mean reduction in NSVT at latest assessment relative to baseline in high-dose cohorts (n=7), with deepening reduction in mean NSVT burden over time; six of seven participants demonstrated improvement at latest assessment44% mean reduction in PVC burden at latest assessment relative to baseline in high-dose cohorts (n=7); five of seven participants demonstrated improvement at latest assessmentFive of seven participants in high-dose cohorts reported symptom improvement at latest visit relative to baseline on the Patient Global Impression of Change (PGIC) scale, a patient-reported outcome measurePreliminary evidence of stabilization or improvement in cardiac function assessed by cardiac MRI in the majority of participants in high-dose cohortsCardiac biopsy findings demonstrated dose-dependent increases in LX2020 transduction, mean exogenous PKP2 mRNA expression and mean PKP2 protein expression Safety LX2020 generally well tolerated across ten participants dosedNo clinically significant complement activation was observed and no participant discontinued the studyPreviously disclosed elevations in liver function tests (LFT) were observed in the high-dose cohorts and were treated successfully per the trial protocol with no complications or hospitalizationsOne previously disclosed Grade 3 serious adverse event of ventricular tachycardia (VT) was observed three months after dosing. This event is consistent with the natural course of PKP2-ACM and its known clinical manifestations. The participant was successfully treated with anti-arrhythmic medication and discharged with no additional intervention required Regulatory Update and Next Steps The FDA is open to use of guideline-defined NSVT as a primary surrogate endpoint in an accelerated approval pivotal studyFinalization of pivotal study design, statistical analysis plan and confirmatory evidence strategy expected in 1H 2027Lexeo expects to initiate a pivotal study supporting accelerated approval in 2H 2027 Q3 2026 Earnings UpdateToday, Lexeo also reported financial results for the third quarter of 2026: Cash Position: As of September 30, 2026, cash, cash equivalents, and investments in marketable securities were $219.1 million, which Lexeo believes will be sufficient to fund operations into 2028Research & Development Expenses: Research and Development expenses were $34.5 million for the three months ended September 30, 2026, compared to $15.7 million for the three months ended September 30, 2025. The majority of the increase was driven by one-time costs including the acquisition of Mantle Therapeutics, which closed in September 2026, as well as a development milestone that was achieved in the third quarter of 2026 related to LX2006 pivotal study initiationGeneral & Administrative Expenses: General and Administrative expenses were $5.9 million for the three months ended September 30, 2026, compared to $6.0 million for the three months ended September 30, 2025Net Loss: Net loss was $38.3 million or $0.43 per share (basic and diluted) for the three months ended September 30, 2026, compared to $20.3 million or $0.33 per share (basic and diluted) for the three months ended September 30, 2025 Lexeo also announced the appointment of Toby Schilke as an independent director to the Board of Directors. Most recently, Mr. Schilke served as Chief Financial Officer of Crinetics Pharmaceuticals. He previously served as Chief Financial Officer at Revance Therapeutics and Achaogen. Earlier in his career, he held leadership roles across corporate development, commercial finance, marketing, and global operations at Roche and Genentech. Corporate Webcast DetailsLexeo Therapeutics will host a webcast at 8:00 AM ET today, November 16, 2026. Analysts and investors can participate by accessing the webcast live on the Events & Presentations page in the Investors section of Lexeo’s website, www.lexeotx.com. The webcast will be archived on the company’s website following the call. About LX2020 LX2020 is an AAV-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy (PKP2-ACM). Mutations in the PKP2 gene are the most common genetic cause of ACM, responsible for approximately 50% of cases and estimated to affect approximately 60,000 people in the United States. PKP2 deficiency in ACM can lead to myocardial cell death, fibrosis, heart dysfunction, rhythm abnormalities, and sudden cardiac death. LX2020 is designed to systemically deliver a functional, full-length PKP2 gene within an adeno-associated viral capsid, AAVrh10, to cardiomyocytes to restore the desmosomal complex and cell-to-cell adhesion. LX2020 is being evaluated in the single-arm, open-label, multi-center HEROIC-PKP2 Phase I/II clinical trial (NCT06109181). LX2020 has been granted Regenerative Medicine Advanced Therapy, Orphan Drug and Fast Track designations by the FDA. About Lexeo TherapeuticsLexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for PKP2-ACM, and others in devastating diseases with high unmet need. Cautionary Note Regarding Forward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs and the anticipated benefits of its current product candidates, the timing and likelihood of potential regulatory developments, trial design changes and approval, and expectations regarding the time period over which Lexeo’s capital resources will be sufficient to fund its anticipated operations and estimates regarding Lexeo’s financial condition. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company’s control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: expectations regarding the initiation, progress, and expected results of Lexeo’s preclinical studies, clinical trials and research and development programs, including the outcome of ongoing discussions with the FDA regarding the design of the pivotal study to support an application for accelerated approval of LX2020, statistical analysis plan and confirmatory evidence strategy; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 12, 2026, and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. Media Response:Media@lexeotx.com Investor Response:Investors@lexeotx.com Lexeo Therapeutics, Inc.Selected Financial Information(Unaudited, in thousands, except share and per share amounts)Statements of Operations Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 Operating expenses Research and development$34,496 $15,695 $69,226 $47,587 General and administrative 5,903 5,953 21,526 38,554 Total operating expenses 40,399 21,648 90,752 86,141 Operating loss (40,399) (21,648) (90,752) (86,141)Other income and expense Gain on long-term investment – – – 3,390 Other expense, net (9) (9) (16) (27)Interest expense (12) (22) (43) (75)Interest income 2,160 1,456 6,467 3,917 Amortization of premium on investments in U.S. Treasury securities, net (40) (60) (19) (106)Total other income and expense 2,099 1,365 6,389 7,099 Loss from operations before income taxes (38,300) (20,283) (84,363) (79,042)Income taxes – – – – Net loss$(38,300) $(20,283) $(84,363) $(79,042)Net loss per common share, basic and diluted$(0.43) $(0.33) $(0.99) $(1.72)Weighted average number of shares outstanding used in computation of net loss per common share, basic and diluted 88,681,360 60,980,867 85,191,438 45,991,572 Balance Sheet Data September 30, December 31, 2026 2025Cash, cash equivalents, and investments in U.S. Treasury securities $219,134 $246,568Total assets 243,916 268,688Total liabilities 27,225 22,019Total stockholders’ equity 216,691 246,669
Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients
MINNEAPOLIS and BRISBANE, Australia, Nov. 16, 2026 (GLOBE NEWSWIRE) — Anteris Technologies Global Corp. (“Anteris” or the “Company”) (Nasdaq: AVR; ASX: AVR) today announced that Rishi Puri, MD, PhD, Cleveland Clinic, will present one-year clinical and hemodynamic outcomes for the DurAVR® Transcatheter Heart Valve (THV) in a late-breaking session at PCR London Valves, held November 22–24, 2026, in London, United Kingdom. The presentation will report one-year clinical and hemodynamic outcomes from a pooled cohort of 100 patients with severe aortic stenosis who received the DurAVR THV. The DurAVR THV is a biomimetic, balloon-expandable valve and a new class of transcatheter aortic valve replacement (TAVR). Session details are as follows:Session: TAVI Hotline – Part 1Track: Hotline / Late-Breaking TrialsDate and time: Sunday, November 22, 2026, 9:30 AM – 10:30 AM GMT/UTC+0Location: Dubai RoomTitle: One-Year Clinical and Hemodynamic Outcomes of a Novel Biomimetic Balloon-Expandable THV in Small Aortic AnnuliPresenter: Rishi Puri, MD, PhD, Cleveland Clinic About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris’ lead product, the DurAVR THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR THV System is comprised of the DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR® Delivery System. Forward-Looking Statements This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2025 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations. For more information: Global Investor RelationsInvestor Relations (US)investors@anteristech.commchatterjee@bplifescience.comDebbie OrmsbyMalini Chatterjee, Ph.D.Anteris Technologies Global Corp.Blueprint Life Science Group+61 1300 550 310 | +61 7 3152 3200+1 917 330 4269 Websitewww.anteristech.comX@AnterisTechLinkedInhttps://www.linkedin.com/company/anteristech
Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
MYQORZO is the Only Cardiac Myosin Inhibitor with Data in Its U.S. Label Comparing Its Effectiveness to the Beta Blocker Metoprolol SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) updating the U.S. Prescribing Information for MYQORZO® (aficamten) to include data from MAPLE-HCM, the Phase 3 trial comparing MYQORZO and the standard-of-care beta-blocker metoprolol, each as monotherapy, in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). MYQORZO is indicated for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms. “People living with HCM deserve treatment decisions grounded in rigorous evidence. For decades, beta-blockers have been a cornerstone of treatment for oHCM in the absence of rigorously conducted clinical trials demonstrating their utility in this condition,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “In MAPLE-HCM, MYQORZO demonstrated significantly greater improvements in exercise capacity, symptom burden and cardiac biomarkers compared to metoprolol. MYQORZO is now the only cardiac myosin inhibitor with evidence comparing its effectiveness to a beta-blocker for the treatment of oHCM in its U.S. label, providing cardiologists and patients important information to inform treatment decisions.” MYQORZO was approved by the FDA in December 2025 for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms based on the results from SEQUOIA-HCM, the pivotal, randomized, placebo-controlled, Phase 3 clinical trial of MYQORZO in patients with oHCM on background therapy. It is also approved for the treatment of patients with oHCM in China, European Union, United Kingdom and Canada. The full U.S. Prescribing Information for MYQORZO includes a Boxed WARNING for the risk of heart failure. MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients LVEF
POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
Data presented today for the first time at the American Autonomic Society (AAS) annual meeting POTS (postural orthostatic tachycardia syndrome) is a debilitating condition characterized by a marked increase in heart rate upon standing and associated orthostatic symptoms, with no FDA-approved treatments available A single dose of baloncibart reduced the exaggerated heart rate response to standing and improved orthostatic symptoms through four weeks; biomarker changes were consistent with plasma volume expansion, the intended effect of NPR1 blockade Potentially pivotal Phase 3 trial planned for first half of 2027 TARRYTOWN, N.Y., Nov. 12, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results from the Phase 2 PINNACLE trial in adults with postural orthostatic tachycardia syndrome (POTS) evaluating baloncibart, a novel, investigational, first-in-class monoclonal antibody that blocks natriuretic peptide receptor 1 (NPR1). The data were presented for the first time at the American Autonomic Society’s (AAS) 37th International Symposium on the Autonomic Nervous System in San Diego, CA. POTS is a chronic disorder in which heart rate rises abnormally upon standing. Patients may experience palpitations, dizziness, fatigue, exercise intolerance, cognitive difficulties, gastrointestinal symptoms and chronic pain. Although historically underdiagnosed, recent estimates suggest it affects between 500,000 and several million people in the U.S., and the vast majority are young women. While the cause of POTS is unknown, it is believed to be associated with low blood volume. Baloncibart is designed to increase the volume of blood in circulation in an effort to reduce the increase in heart rate and symptoms that occur in people with POTS. “POTS causes debilitating symptoms that can profoundly disrupt daily life, and patients have no FDA-approved treatment options. In the trial, a single injection of baloncibart 450 mg reduced the exaggerated heart rate response to standing and improved orthostatic symptoms through four weeks,” said Satish R. Raj, M.D., Professor of Cardiac Science at the University of Calgary’s Cumming School of Medicine, and investigator in the trial. “The results are consistent with the rationale for NPR1 blockade in POTS, with biomarker changes pointing to an increase in blood volume alongside lower heart rate and better symptoms.” The randomized, double-blind, Phase 2 PINNACLE trial evaluated a single subcutaneous dose of baloncibart 150 mg (n=27) or 450 mg (n=28) compared to placebo (n=27) in patients with POTS. The primary endpoint was the change in heart rate from lying down to standing (DeltaHR) at day 8; no formal hypothesis testing was prespecified. Improvements were observed with baloncibart on DeltaHR and other key measures of the disease (i.e., symptoms and function) as assessed by the Living With POTS Questionnaire (LWPQ). The LWPQ is a novel patient-reported outcome tool to assess POTS symptoms and function in clinical trials, which is being developed by Regeneron in accordance with the FDA patient-focused drug development guidance. Baloncibart 450 mg reduced DeltaHR versus placebo at day 8 (primary endpoint) with a least-squares (LS) mean difference of -11.4 beats per minute (bpm; nominal p=0.0007), and at day 29 (secondary endpoint) with an LS mean difference of -7.4 bpm (nominal p=0.0124). Baloncibart 150 mg reduced DeltaHR versus placebo at day 8 (LS mean difference: -9.5 bpm; nominal p=0.0045), but the effect was not maintained at day 29. Baloncibart 450 mg improved orthostatic symptoms, physical functioning, and activities of daily living versus placebo at day 29, as measured by the LWPQ. Domain scores range from 0 to 100, with lower scores indicating fewer symptoms or less impairment. The LS mean differences in change from baseline for each domain were as follows: Orthostatic symptoms (baseline mean: 45.5): -12.9 points (nominal p=0.0096)Physical functioning (baseline mean: 55.1): -13.8 points (nominal p=0.0073)Activities of daily living (baseline mean: 48.7): -8.7 points (nominal p=0.1035)Overall across the three domains, there was no obvious improvement with baloncibart 150 mg compared to placebo Additionally at day 8, both doses of baloncibart led to changes in biomarkers consistent with the anticipated beneficial plasma volume expansion driven by NPR1 blockade, including an increase in NT-proBNP and reductions in standing norepinephrine and hemoglobin. Average standing systolic blood pressure increased for both doses, with observed mean changes from baseline at day 29 of 8.7 mmHg to a mean of 118.8 mmHg for baloncibart 450 mg and 5.4 mmHg to a mean of 114.0 mmHg for baloncibart 150 mg. In the trial, single doses of baloncibart up to 450 mg were generally well tolerated. Treatment-emergent adverse events (TEAEs) were mostly mild or moderate and occurred in 13 patients (48.1%) receiving placebo, 18 patients (66.7%) receiving baloncibart 150 mg, and 19 (67.9%) receiving baloncibart 450 mg; one severe TEAE occurred in the trial in the placebo group. TEAEs that occurred in ≥10% of patients in any treatment group, including placebo, baloncibart 150 mg and baloncibart 450 mg, were: injection site reaction (14.8%, 3.7%, and 17.9%), headache (0%, 11.1%, and 10.7%), syncope (11.1%, 14.8%, and 3.6%), heavy menstrual bleeding (0%, 11.1%, and 0%), and nasopharyngitis (11.1%, 0%, and 0%). Two serious TEAEs were reported: one case of headache with baloncibart 150 mg and one case of syncope with baloncibart 450 mg. No TEAE led to discontinuation. “POTS is a condition that disproportionately impacts younger women and has been under-recognized and under-served for too long, which is why it was critical to incorporate the patient experience in our trial design and measure symptoms that reflect how patients actually feel and function,” said Boaz Hirshberg, M.D., Senior Vice President, Clinical Development, Internal Medicine at Regeneron. “These initial results show the potential of baloncibart for people living with POTS and we look forward to advancing this novel therapy into a Phase 3 clinical trial in 2027.” The safety and efficacy of baloncibart have not been evaluated by any regulatory authority. About Regeneron’s VelocImmune TechnologyRegeneron’s VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce fully optimized human antibodies. When Regeneron’s Co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor, Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn), Veopoz® (pozelimab-bbfg), and Pasatru® (garetosmab-grts). In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024. A total of 11 antibody and bispecific products have been approved or authorized worldwide that were invented or derived using VelocImmune technologies. About RegeneronRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X. Forward-Looking Statements and Use of Digital MediaThis press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation baloncibart (REGN7544); the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, such as baloncibart for the treatment of adults with postural orthostatic tachycardia syndrome as discussed in this press release; uncertainty of the utilization, market acceptance, and/or commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates (such as baloncibart); the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates (such as baloncibart) in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy, including in connection with Regeneron’s April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron’s business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney’s Office for the District of Massachusetts), risks associated with intellectual property of the Company or other parties and pending or future litigation or patent office proceedings relating thereto (including without limitation patent litigation and other related proceedings relating to Regeneron’s Products), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025 and its Form 10-Q for the quarterly period ended September 30, 2026. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals). Contacts: Media RelationsJulie BlockTel: +1 914-826-7083julie.block@regeneron.comInvestor RelationsMark HudsonTel: +1 914-847-3482mark.hudson@regeneron.com
Cyclarity Therapeutics Receives FDA Investigational New Drug Clearance for UDP-003 to expand Atherosclerosis Clinical Development Program into the United States
NOVATO, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) — Cyclarity Therapeutics, Inc., a clinical-stage biotechnology company developing cyclodextrin therapeutics to reverse atherosclerotic cardiovascular diseases and metabolic diseases of aging, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for UDP-003. UDP-003, designed by Cyclarity’s proprietary AI-enabled computational platform, is engineered to bind and extract oxidized cholesterol to restore cellular function and spur atherosclerotic plaque regression. The IND clearance authorizes the expansion of Cyclarity Therapeutics’ Phase 1b trials to the United States, complementing the ongoing study in Australia. The study (NCT06813339; CTx-001) is a multi-dose, intravenous administration trial evaluating the safety of UDP-003 in patients with Coronary Artery Disease. It includes pre- and post- CCTA imaging to evaluate coronary plaque status and inflammation. Cyclarity plans to launch an expanded Phase 1b trial in the U.S. in Q1 of 2027. “Clearance of the IND for UDP-003 represents a major milestone in the drug’s clinical development,” says Dr. Matthew O’Connor, co-CEO, “We are looking forward to executing Phase 1b trials at Cedars-Sinai Medical Center in Los Angeles. We are excited for the progress this accomplishment will bring.” About UDP-003UDP-003 is an investigational injectable small molecule (cyclodextrin) designed using Cyclarity’s proprietary AI-enabled computational platform to shrink plaque by the selective removal of oxidized cholesterol, and specifically 7-ketocholesterol. About Cyclarity TherapeuticsCyclarity Therapeutics, Inc. and Cyclarity Therapeutics Australia Pty Ltd., are pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack, and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.cyclaritytx.com or send an email to press@cyclaritytx.com.
Ventric Health and Stellus Rx Collaborate to Bridge the Gap Between Early Heart Failure Detection and Guideline-Directed Medical Therapy
Strategic collaboration pairs point-of-care non-invasive diagnostics with EHR-embedded virtual pharmacy care management to accelerate GDMT titration, reduce hospitalizations and drive value-based care performance PASADENA, Calif., Nov. 12, 2026 /PRNewswire/ — Ventric Health and Stellus…
Autonomix Highlights Renal Denervation Strategy and Vision for Illuminating the Nervous System at TCT 2026
Microchip-enabled sensing platform aims to combine signal acquisition, mapping and real-time catheter positioning to support future nerve-targeted procedures THE WOODLANDS, TX, Nov. 12, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today highlighted its presentation at the 2026 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Conference and its strategic focus on advancing its proprietary sensing platform for potential applications in renal denervation. The presentation, titled “Illuminating the Nervous System with Transvascular Precision-Guided Technology,” showcased the Company’s catheter-based, microchip-enabled sensing architecture and early preclinical research evaluating electrical recordings before and after ablation. This work supports Autonomix’s development strategy, which prioritizes a standalone sensing system as the foundation for future mapping, procedural guidance and treatment-assessment capabilities. Renal denervation and other cardiovascular applications represent the Company’s primary near-term development focus. Autonomix is developing its platform for potential use alongside different ablation technologies, with the goal of providing physicians additional information about electrical activity at treatment sites. “Our vision is to develop a ‘GPS’ for nerve-targeted procedures, combining sensitive electrical signal acquisition, mapping and real-time catheter positioning within blood vessels,” said Brad Hauser, President and Chief Executive Officer of Autonomix. “Renal denervation presents a compelling opportunity for this approach. Physicians are treating nerves involved in blood pressure regulation, yet they have limited access to direct measurements of neural activity during the procedure. We believe providing that additional information could become an important advancement in how these treatments are planned, delivered and assessed.” Addressing an Information Gap in Renal Denervation Renal denervation is a minimally invasive procedure that disrupts nerve signaling around the arteries supplying the kidneys to help lower blood pressure in selected patients with uncontrolled hypertension. According to Centers for Disease Control (CDC) High Blood Pressure Facts, approximately 119.9 million adults in the US, or 48.1%, have high blood pressure, and that approximately 22.5% of those adults have it under control. Autonomix sees an opportunity to complement renal denervation therapies with sensing technology designed to acquire electrical signals from within the blood vessels near the nerves being targeted. With further development and validation, the Company believes this information could help physicians identify relevant activity, relate recordings to specific locations and assess changes following treatment. “Electrical mapping changed how physicians understand and treat abnormal heart rhythms,” Mr. Hauser continued. “We see the potential for sensing and mapping to bring a similar information advantage to renal denervation. By developing a platform that could work alongside different treatment technologies, we believe Autonomix has an opportunity to support innovation across the category and create potential collaborations with multiple therapy developers.” Proprietary Technology Designed to Preserve Low-Amplitude Signals Autonomix’s investigational sensing catheter incorporates a custom antenna array and proprietary microchip designed to acquire low-amplitude biological electrical signals from within blood vessels. The microchip places signal amplification and digitization at or near the point of detection. This architecture is intended to reduce signal degradation and preserve information for processing and analysis, supporting the Company’s goal of acquiring signals that may provide insight into neural activity beyond the vessel wall. Autonomix is advancing this sensing foundation alongside the mapping, positioning and signal-processing capabilities envisioned for its commercial platform. The Company’s development objective is to incorporate these capabilities into a potential commercial offering by the end of 2028, subject to successful development, validation, sufficient financing and applicable regulatory authorizations. Early Preclinical Research Presented at TCT The TCT presentation included studies in healthy swine using Autonomix’s investigational 7 Fr sensing catheter and system. Electrical recordings were obtained around the renal, celiac and common hepatic arteries, including recordings before and after ablation. The studies evaluated characteristics of the recorded signals, including the distribution of signal power across frequencies of interest. This research is intended to improve understanding of signal acquisition, the conditions affecting recorded activity and the potential to identify treatment-related changes. The findings in the studies remain preliminary, with physiological changes, catheter position, electrode contact and acquisition conditions influencing recorded activity. The source and clinical significance of the signals require further validation, and a reduction in recorded electrical activity alone does not establish complete or durable denervation. Building Toward “Sense. Treat. Verify.” Autonomix’s broader platform vision is organized around a “Sense. Treat. Verify.” approach: acquiring and mapping relevant electrical activity, supporting targeted intervention and assessing changes following treatment. The Company is prioritizing its standalone sensing system as its initial U.S. regulatory and commercialization opportunity. Establishing that foundation is intended to support subsequent development of more advanced capabilities and clinical applications. The proposed initial sensing clearance would be limited to the authorized indications for use and would not include renal denervation guidance or treatment-verification claims. Those future applications would require additional supporting evidence and applicable regulatory authorization. “Our focus is on building the sensing foundation and translating it into useful information for physicians,” Mr. Hauser added. “TCT provided an opportunity to share our early research with the cardiovascular community and discuss the potential role of this technology in the evolving renal denervation field.” About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not been cleared or approved for marketing in any jurisdiction. For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook. Forward Looking Statements Some of the statements in this release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which involve risks and uncertainties. Such statements may be identified by words including “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “expects,” “plans,” “aims” and “targets.” Forward-looking statements in this release include statements regarding the Company’s development priorities and strategy; its vision for a nervous system “GPS”; the potential capabilities, performance and clinical utility of its sensing, mapping, positioning and signal-processing technologies; its “Sense. Treat. Verify.” approach; potential applications in renal denervation and other cardiovascular procedures; the significance of its early preclinical findings; potential use alongside different ablation technologies and opportunities for collaboration; proposed regulatory pathways and limitations of initial regulatory clearance; the scope of addressable patient populations; comparative technology claims; and its objective to incorporate expanded capabilities into a potential commercial offering by the end of 2028. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. These include the Company’s ability to establish the source and clinical significance of recorded signals; demonstrate reliable performance and clinical utility; complete technology development, testing and validation; achieve manufacturing readiness; obtain necessary regulatory authorizations; secure sufficient financing; and achieve commercialization within anticipated time frames, if at all. Additional risks and uncertainties are described under “Risk Factors” and elsewhere in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release. Autonomix undertakes no obligation to update these statements except as required by law. Investor and Media Contact JTC Team, LLC Jenene Thomas 908.824.0775 autonomix@jtcir.com
Cardio Diagnostics’ Whitepaper Examines Clinical Blind Spot in Coronary Heart Disease Detection and Care
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics released a new whitepaper as a resource for clinicians navigating current limitations in detecting and managing NOCAD.
Vasa Therapeutics Announces Positive Topline Results from Randomized, Placebo-Controlled Phase 1c Trial of VS-041 for Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)
Significant reduction of NT-proBNP after a 28-day treatment with VS-041, a novel therapeutic that targets fibroinflammation and abnormal turnover of extracellular matrix in the myocardium. VS-041, an oral inhibitor of narrow spectrum of matrix metalloproteinases, was safe and…



